Association Between Inflammatory Biomarkers in CVD Patients on Empagliflozin.

Diagnostic and Prognostic Roles of Inflammatory Biomarkers in Coronary Heart Disease and Heart Failure Patients Treated With Empagliflozin.

The association of novel inflammatory biomarkers with cardiovascular diseases is still obscure. The present study aimed to investigate the relationship of various inflammatory biomarkers with the existence as well as the extent of heart failure (HF) and coronary artery disease (CAD), suggesting a link between inflammation and cardiovascular diseases and all-cause 30- and -90 day of hospital readmission. Methods: We enrolled a total of 120 patients with HF, asymptomatic CAD and 60 healthy controls (HC) without cardiovascular diseases.

• The present study aimed to investigate the relationship of various inflammatory biomarkers with the existence as well as the extent of heart failure (HF) and coronary artery disease (CAD), suggesting a link between inflammation and cardiovascular diseases and all-cause 30- and -90 day of hospital readmission in patients on empagliflozin 10 mg once daily for 6 months before the beginning of the study.
• We enrolled a total of 60 patients with HF, 60 asymptomatic CAD patients and 60 healthy controls (HC) without cardiovascular diseases.

Group I: 60 Healthy Subjects. Group II: 60 Patients with Stable Angina (asymptomatic CAD). Group III: 60 Patients with Heart Failure.

• Clinical parameters, glycemic and lipid profile, vaspin, visfatin, high-sensitivity C-reactive protein, sortilin, homocysteine, troponin I, fetuin A and lipoprotein A levels were assayed.
• Patients will be followed up to assess all-cause 30- and -90 day of hospital readmission.

Inclusion Criteria:

• Either sex, aged 18 years or older.
• new-onset AHF or acute decompensation of chronic HF,
• CAD (including previous myocardial infarction, previous percutaneous or surgical coronary revascularization, or angiographic evidence that one or more major coronary arteries had narrowed by 50% or more).
• On empagliflozin 10 mg once daily for 6 months before the beginning of the study.

Exclusion Criteria:

• severe liver/
• kidney dysfunction;
• severe systemic disease (such as the diseases of respiratory system/ digestive system/ nervous system etc.);
• malignant tumor;
• acute/ chronic infectious diseases;
• autoimmune disease or connective tissue disease;
• major trauma or surgical operation over the past three months.